obatoclax mesylate

DRUG10 trials

Sponsors

Gemin X, National Cancer Institute (NCI), M.D. Anderson Cancer Center

Conditions

Acute Leukemias of Ambiguous LineageAcute Undifferentiated LeukemiaAdult Non-Hodgkin LymphomaAngioimmunoblastic T-cell LymphomaB-cell Chronic Lymphocytic LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Burkitt LymphomaChildhood Chronic Myelogenous Leukemia

Phase 1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

CompletedNCT00407303

Gemin XMantle-Cell Lymphoma

Start: 2006-10-31End: 2009-11-30Updated: 2016-07-21

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

CompletedNCT00521144

National Cancer Institute (NCI)Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2007-08-31End: 2010-08-31Updated: 2015-05-05

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

TerminatedNCT00538187

National Cancer Institute (NCI)Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma +5

Start: 2007-12-31Updated: 2015-12-04

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

TerminatedNCT00612612

National Cancer Institute (NCI)B-cell Chronic Lymphocytic Leukemia, Leukemia, Prolymphocytic Leukemia +5

Start: 2008-01-31Updated: 2013-09-30

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

TerminatedNCT00719901

National Cancer Institute (NCI)Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage II Multiple Myeloma +1

Start: 2008-07-31End: 2012-06-30Updated: 2015-01-12

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

TerminatedNCT00724841

Gemin XMetastatic Melanoma

Start: 2008-06-30End: 2010-08-31Updated: 2016-07-22

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

TerminatedNCT00933985

National Cancer Institute (NCI)Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma +26

Start: 2009-06-30End: 2013-04-30Updated: 2014-05-01

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

WithdrawnNCT01238146

National Cancer Institute (NCI)Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma +4

Start: 2010-10-31Updated: 2013-06-06

Phase 2

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

CompletedNCT00427856

Gemin XLymphoma, Follicular

Start: 2007-03-31End: 2009-07-31Updated: 2016-07-22

Obatoclax for Systemic Mastocytosis

TerminatedNCT00918931

M.D. Anderson Cancer CenterLeukemia, Systemic Mastocytosis

Start: 2009-06-30End: 2010-10-31Updated: 2011-11-04

Related Papers

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

PLoS ONE2014-10-0677 citations